Related Experiment Video

Updated: May 11, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

[Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis]

Karen Schreiber1, Ana Voldsgaard, Per Soelberg Sørensen

  • 1Dansk Multipel Sclerose Center, Afsnit 2082 N5, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark. karen.schreiber@rh.dk

Ugeskrift for Laeger
|May 14, 2013
PubMed

Insights

Interferon beta 1b (IFN-beta) did not prevent permanent disability in secondary progressive multiple sclerosis (SPMS). However, it significantly reduced relapse risk and short-term disability, guiding treatment recommendations.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Interferon beta 1b (IFN-beta) is an approved treatment for relapsing secondary progressive multiple sclerosis (SPMS) in the EU.
  • Evidence regarding the efficacy of IFN-beta in SPMS requires comprehensive evaluation.

Purpose of the Study:

  • To systematically review and meta-analyze randomized controlled trials evaluating the efficacy of IFN-beta versus placebo in patients with SPMS.
  • To assess the impact of IFN-beta on disability progression, relapse rates, and relapse-related disability in SPMS.

Main Methods:

  • A Cochrane review of double- or single-blinded randomized placebo-controlled studies.
  • Meta-analysis included five studies with a total of 3,122 patients (1,829 receiving IFN-beta).

Main Results:

  • IFN-beta did not prevent the development of permanent physical disability in SPMS patients.
  • IFN-beta significantly reduced the risk of relapse and short-term relapse-related disability.

Conclusions:

  • IFN-beta demonstrates efficacy in reducing relapses and short-term disability in SPMS.
  • Treatment decisions for IFN-beta 1b in SPMS should consider individual patient profiles, focusing on relapsing or rapidly progressing disease, with regular efficacy evaluations and discontinuation if progression persists.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...